Comparative Pharmacology
Head-to-head clinical analysis: CLOLAR versus HALAVEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOLAR versus HALAVEN.
CLOLAR vs HALAVEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.
Halaven (eribulin mesylate) is a microtubule dynamics inhibitor. It binds to tubulin, suppressing microtubule growth and sequestering tubulin into nonfunctional aggregates, leading to G2/M cell cycle arrest and apoptosis.
5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.
1.4 mg/m2 intravenously over 2-5 minutes on days 1 and 8 of a 21-day cycle.
None Documented
None Documented
Terminal elimination half-life approximately 5.2 hours in patients with normal renal function; prolonged in renal impairment (up to 9.8 hours with CrCl <60 mL/min) and in elderly; clinical context: supports once-daily dosing adjustment for renal function.
Terminal elimination half-life approximately 30-50 hours (mean 40 hours). Clinically, this supports weekly dosing schedule.
Renal: 50-60% as unchanged drug; biliary/fecal: minimal (<5%)
Primarily biliary/fecal: ~70-80% as unchanged drug and metabolites in feces; renal excretion accounts for <10% (mostly metabolites).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent